Celltrion Sees ‘Record-High Revenue’ With Increasing Infliximab Sales
As Company Plans To Launch One Biological Product Every Year
Executive Summary
South Korea’s Celltrion has delivered a strong fourth quarter in FY21 based on the increase in infliximab sales across all markets as well as a contribution from its Regkirona COVID-19 treatment. The company expects modest top-line growth to continue by launching at least one biological product every year.
You may also be interested in...
Celltrion’s Vegzelma Becomes Fourth US-Approved Bevacizumab
Celltrion’s Vegzelma earns a long-awaited USFDA approval. The oncology biosimilar will be up against established bevacizumab products from Amgen and Pfizer as well as recent newcomer Amneal.
The Generics Bulletin Top 50, Part Two: Mid-Table Movements See Firms Jostle For Position
Medium-sized generics and biosimilars players have seen ups and downs over the past year, with some changes to the order of these mid-table players seen as we continue to work our way through Generics Bulletin’s annual Top 50.
Eurofarma Biosimilars Deal Broadens Access To Latin America For Henlius
Shanghai Henlius Biotech has announced a licensing deal for three biosimilars – bevacizumab, rituximab and trastuzumab – with Brazil’s Eurofarma. The agreement, which could be worth as much as $50.5m, gives the Chinese company enhanced access to Latin America as it continues to broaden its global footprint.